Today, in the area of Biomolecular Screening, it would seem that 'some
thing better' in terms of instrumentation or assay technology, is emer
ging almost every week. From the standpoint of planning, this presents
significant challenges to decide whether to integrate the 'latest and
greatest' advance, whether to wait just a few months for the next adv
ance, which may make the current advance obsolete, or perhaps to maint
ain the status quo. This decision would be considerably simpler if the
re was a clear, optimal strategy for identifying and selecting lead co
mpound This article attempts to look at this issue from the perspectiv
e of discussing the pros and cons to several approaches to lead discov
ery.